Suchergebnisse - "Fajgenbaum, David C."

PubPharm (4)

1

Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease

enthalten in: Blood advances | 2022

von van Rhee, F. | Rosenthal, A. | Kanhai, K. | +4

2

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease

enthalten in: American journal of hematology | 2020

von Fajgenbaum, D. | Wu, D. | Goodman, A. | +21

3

Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease

enthalten in: Blood | 2019

von Zhang, L. | Zhao, A. | Duan, M. | +7

CommentIn: Blood. 2019 Apr 18;133(16):1697-1698. - PMID 31000513

4

Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease : secondary analyses of phase II clinical trial data

enthalten in: British journal of haematology | 2019

von Morra, D. | Pierson, S. | Shilling, D. | +6

1
[1]